Intrapatient variability of tacrolimus trough level may be not the cause, but an indirect parameter of comorbidities: Editorial on "Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation".
作者信息
Kim Jongman
机构信息
Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
出版信息
Clin Mol Hepatol. 2025 Apr;31(2):589-591. doi: 10.3350/cmh.2025.0076. Epub 2025 Jan 24.
Abstract
摘要
相似文献
1
Intrapatient variability of tacrolimus trough level may be not the cause, but an indirect parameter of comorbidities: Editorial on "Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation".
Clin Mol Hepatol. 2025 Apr;31(2):589-591. doi: 10.3350/cmh.2025.0076. Epub 2025 Jan 24.
2
Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation.
Clin Mol Hepatol. 2025 Jan;31(1):131-146. doi: 10.3350/cmh.2024.0451. Epub 2024 Oct 2.
3
Tacrolimus levels and variability in CKD and ESRD risk post-liver transplant: Letter to the editor on "Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation".
Clin Mol Hepatol. 2025 Apr;31(2):e137-e139. doi: 10.3350/cmh.2024.1159. Epub 2025 Jan 9.
4
Correspondence to editorial on "Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation".
Clin Mol Hepatol. 2025 Apr;31(2):e161-e162. doi: 10.3350/cmh.2025.0121. Epub 2025 Feb 13.
5
Correspondence to letter to the editor on "Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation".
Clin Mol Hepatol. 2025 Apr;31(2):e212-e214. doi: 10.3350/cmh.2025.0100. Epub 2025 Feb 10.
6
High Intrapatient Variability in Tacrolimus Exposure Is Not Associated With Immune-mediated Graft Injury After Liver Transplantation.
Transplantation. 2019 Nov;103(11):2329-2337. doi: 10.1097/TP.0000000000002680.
7
Patterns in Tacrolimus Variability and Association with Donor-Specific Antibody Formation in Pediatric Kidney Transplant Recipients.
Clin J Am Soc Nephrol. 2022 Aug;17(8):1194-1203. doi: 10.2215/CJN.16421221. Epub 2022 Jul 26.
8
Tacrolimus Trough Concentration Variability and Disparities in African American Kidney Transplantation.
Transplantation. 2017 Dec;101(12):2931-2938. doi: 10.1097/TP.0000000000001840.
9
Intrapatient Variability in Tacrolimus Exposure Does Not Predict The Development of Cardiac Allograft Vasculopathy After Heart Transplant.
Exp Clin Transplant. 2018 Jun;16(3):326-332. doi: 10.6002/ect.2016.0366. Epub 2017 Sep 30.
10
Tacrolimus trough-level variability predicts long-term allograft survival following kidney transplantation.
J Nephrol. 2016 Apr;29(2):269-276. doi: 10.1007/s40620-015-0230-0. Epub 2015 Sep 15.
引用本文的文献
1
Correspondence to editorial on "Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation".
Clin Mol Hepatol. 2025 Apr;31(2):e161-e162. doi: 10.3350/cmh.2025.0121. Epub 2025 Feb 13.
本文引用的文献
1
Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation.
Clin Mol Hepatol. 2025 Jan;31(1):131-146. doi: 10.3350/cmh.2024.0451. Epub 2024 Oct 2.
2
Factors and interventions affecting tacrolimus intrapatient variability: A systematic review and meta-analysis.
Transplant Rev (Orlando). 2024 Dec;38(4):100878. doi: 10.1016/j.trre.2024.100878. Epub 2024 Sep 7.
3
Asian Pacific Association for the Study of the Liver clinical practice guidelines on liver transplantation.
Hepatol Int. 2024 Apr;18(2):299-383. doi: 10.1007/s12072-023-10629-3. Epub 2024 Feb 28.
4
Renal safety of tenofovir disoproxil fumarate and entecavir in liver transplant patients: a nationwide Korean registry study.
Hepatol Int. 2022 Jun;16(3):537-544. doi: 10.1007/s12072-022-10320-z. Epub 2022 Apr 23.
5
Outcomes after liver transplantation in Korea: Incidence and risk factors from Korean transplantation registry.
Clin Mol Hepatol. 2021 Jul;27(3):451-462. doi: 10.3350/cmh.2020.0292. Epub 2021 Feb 2.
6
Tacrolimus intrapatient variability in solid organ transplantation: A multiorgan perspective.
Pharmacotherapy. 2021 Jan;41(1):103-118. doi: 10.1002/phar.2480. Epub 2020 Dec 24.
7
Effect of on the Once-Daily Tacrolimus Conversion in Stable Liver Transplant Patients.
J Clin Med. 2020 Sep 8;9(9):2897. doi: 10.3390/jcm9092897.
8
High Intrapatient Variability of Tacrolimus Concentrations Predicts Accelerated Progression of Chronic Histologic Lesions in Renal Recipients.
Am J Transplant. 2016 Oct;16(10):2954-2963. doi: 10.1111/ajt.13803. Epub 2016 Apr 21.
9
Chronic kidney disease and associated mortality after liver transplantation--a time-dependent analysis using measured glomerular filtration rate.
J Hepatol. 2014 Aug;61(2):286-92. doi: 10.1016/j.jhep.2014.03.034. Epub 2014 Apr 5.
10
Tacrolimus trough levels, rejection and renal impairment in liver transplantation: a systematic review and meta-analysis.
Am J Transplant. 2012 Oct;12(10):2797-814. doi: 10.1111/j.1600-6143.2012.04140.x.
Zotero 插件